1. Scrip
  2. >>Therapy Areas

ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem

Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is working on a medicinal chemistry "trick" to enable it to develop drugs which inhibit Rho Kinase (ROCK) without causing the unwanted side-effects that have tended to interfere with the development of such compounds.

Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is working on a medicinal chemistry "trick" to enable it to develop drugs which inhibit Rho Kinase (ROCK) without causing the unwanted side-effects that have tended to interfere with the development of such compounds.

Amakem's founding concept is its Localized Drug Action platform, through which it can tweak compounds that target kinases to ensure...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.